Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer

Maria T S Bertilaccio, Matteo Grioni, Brent W. Sutherland, Elena Degl'Innocenti, Massimo Freschi, Elena Jachetti, Norman M. Greenberg, Angelo Corti, Matteo Bellone

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-α derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC. METHODS. Wild type C57BL/6 mice bearing androgen-independent TRAMP-C1 PC and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which spontaneously develop PC and metastasis, were treated with repeated cycles of doxorubicin, administered either alone or following NGR-TNF. Tumor growth and drug uptake by cancer cells was evaluated. RESULTS. Doxorubicin as a single agent blocked the growth of TRAMP-C1 cells in vitro but not in vivo. Pre-treatment of mice bearing subcutaneous TRAMP-C1 tumors with NGR-TNF favored doxorubicin penetration into the tumor mass, and in both TRAMP-C1 and TRAMP models significantly delayed tumor growth without increasing drug-related toxicity. CONCLUSIONS. Pre-treatment with NGR-TNF significantly expanded the therapeutic index of doxorubicin in mouse models of hormone-dependent and -independent PC.

Original languageEnglish
Pages (from-to)1105-1115
Number of pages11
JournalProstate
Volume68
Issue number10
DOIs
Publication statusPublished - Jul 1 2008

Fingerprint

Doxorubicin
Prostatic Neoplasms
Transgenic Mice
Tumor Necrosis Factor-alpha
Prostate
Adenocarcinoma
Neoplasms
Therapeutics
Growth
Drug-Related Side Effects and Adverse Reactions
Inbred C57BL Mouse
Pharmaceutical Preparations
Androgens
Permeability
Hormones
Neoplasm Metastasis

Keywords

  • Androgen-independent
  • CD13
  • Chemotherapy
  • Cytokines
  • Mouse model
  • TRAMP

ASJC Scopus subject areas

  • Urology

Cite this

Bertilaccio, M. T. S., Grioni, M., Sutherland, B. W., Degl'Innocenti, E., Freschi, M., Jachetti, E., ... Bellone, M. (2008). Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate, 68(10), 1105-1115. https://doi.org/10.1002/pros.20775

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. / Bertilaccio, Maria T S; Grioni, Matteo; Sutherland, Brent W.; Degl'Innocenti, Elena; Freschi, Massimo; Jachetti, Elena; Greenberg, Norman M.; Corti, Angelo; Bellone, Matteo.

In: Prostate, Vol. 68, No. 10, 01.07.2008, p. 1105-1115.

Research output: Contribution to journalArticle

Bertilaccio, MTS, Grioni, M, Sutherland, BW, Degl'Innocenti, E, Freschi, M, Jachetti, E, Greenberg, NM, Corti, A & Bellone, M 2008, 'Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer', Prostate, vol. 68, no. 10, pp. 1105-1115. https://doi.org/10.1002/pros.20775
Bertilaccio MTS, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate. 2008 Jul 1;68(10):1105-1115. https://doi.org/10.1002/pros.20775
Bertilaccio, Maria T S ; Grioni, Matteo ; Sutherland, Brent W. ; Degl'Innocenti, Elena ; Freschi, Massimo ; Jachetti, Elena ; Greenberg, Norman M. ; Corti, Angelo ; Bellone, Matteo. / Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. In: Prostate. 2008 ; Vol. 68, No. 10. pp. 1105-1115.
@article{73885e0dd8274576808ac904b73fd9cd,
title = "Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer",
abstract = "BACKGROUND. Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-α derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC. METHODS. Wild type C57BL/6 mice bearing androgen-independent TRAMP-C1 PC and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which spontaneously develop PC and metastasis, were treated with repeated cycles of doxorubicin, administered either alone or following NGR-TNF. Tumor growth and drug uptake by cancer cells was evaluated. RESULTS. Doxorubicin as a single agent blocked the growth of TRAMP-C1 cells in vitro but not in vivo. Pre-treatment of mice bearing subcutaneous TRAMP-C1 tumors with NGR-TNF favored doxorubicin penetration into the tumor mass, and in both TRAMP-C1 and TRAMP models significantly delayed tumor growth without increasing drug-related toxicity. CONCLUSIONS. Pre-treatment with NGR-TNF significantly expanded the therapeutic index of doxorubicin in mouse models of hormone-dependent and -independent PC.",
keywords = "Androgen-independent, CD13, Chemotherapy, Cytokines, Mouse model, TRAMP",
author = "Bertilaccio, {Maria T S} and Matteo Grioni and Sutherland, {Brent W.} and Elena Degl'Innocenti and Massimo Freschi and Elena Jachetti and Greenberg, {Norman M.} and Angelo Corti and Matteo Bellone",
year = "2008",
month = "7",
day = "1",
doi = "10.1002/pros.20775",
language = "English",
volume = "68",
pages = "1105--1115",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer

AU - Bertilaccio, Maria T S

AU - Grioni, Matteo

AU - Sutherland, Brent W.

AU - Degl'Innocenti, Elena

AU - Freschi, Massimo

AU - Jachetti, Elena

AU - Greenberg, Norman M.

AU - Corti, Angelo

AU - Bellone, Matteo

PY - 2008/7/1

Y1 - 2008/7/1

N2 - BACKGROUND. Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-α derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC. METHODS. Wild type C57BL/6 mice bearing androgen-independent TRAMP-C1 PC and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which spontaneously develop PC and metastasis, were treated with repeated cycles of doxorubicin, administered either alone or following NGR-TNF. Tumor growth and drug uptake by cancer cells was evaluated. RESULTS. Doxorubicin as a single agent blocked the growth of TRAMP-C1 cells in vitro but not in vivo. Pre-treatment of mice bearing subcutaneous TRAMP-C1 tumors with NGR-TNF favored doxorubicin penetration into the tumor mass, and in both TRAMP-C1 and TRAMP models significantly delayed tumor growth without increasing drug-related toxicity. CONCLUSIONS. Pre-treatment with NGR-TNF significantly expanded the therapeutic index of doxorubicin in mouse models of hormone-dependent and -independent PC.

AB - BACKGROUND. Poor penetration and uneven distribution of doxorubicin in tumors limits the efficacy of this drug in patients with prostate cancer (PC). Aim of the study was to investigate whether pre-treatment with NGR-TNF, a tumor necrosis factor-α derivative able to target tumor vessels and alter vessel permeability, increases the penetration and the efficacy of doxorubicin in pre-clinical models of PC. METHODS. Wild type C57BL/6 mice bearing androgen-independent TRAMP-C1 PC and transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which spontaneously develop PC and metastasis, were treated with repeated cycles of doxorubicin, administered either alone or following NGR-TNF. Tumor growth and drug uptake by cancer cells was evaluated. RESULTS. Doxorubicin as a single agent blocked the growth of TRAMP-C1 cells in vitro but not in vivo. Pre-treatment of mice bearing subcutaneous TRAMP-C1 tumors with NGR-TNF favored doxorubicin penetration into the tumor mass, and in both TRAMP-C1 and TRAMP models significantly delayed tumor growth without increasing drug-related toxicity. CONCLUSIONS. Pre-treatment with NGR-TNF significantly expanded the therapeutic index of doxorubicin in mouse models of hormone-dependent and -independent PC.

KW - Androgen-independent

KW - CD13

KW - Chemotherapy

KW - Cytokines

KW - Mouse model

KW - TRAMP

UR - http://www.scopus.com/inward/record.url?scp=45749129790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749129790&partnerID=8YFLogxK

U2 - 10.1002/pros.20775

DO - 10.1002/pros.20775

M3 - Article

C2 - 18437689

AN - SCOPUS:45749129790

VL - 68

SP - 1105

EP - 1115

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 10

ER -